Interstitial pneumonitis associated with trastuzumab emtansine

J Oncol Pharm Pract. 2019 Oct;25(7):1798-1800. doi: 10.1177/1078155218813716. Epub 2018 Nov 14.

Abstract

Trastuzumab emtansine is an antibody-drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3-4 toxicities are rare. Pulmonary complications were rarely reported. Here we present a patient presenting with dyspnea after trastuzumab emtansine therapy and treated with a diagnosis of interstitial pneumonitis.

Keywords: Trastuzumab emtansine; breast cancer; interstitial pneumonitis.

Publication types

  • Case Reports

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Aged
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Breast Neoplasms / drug therapy*
  • Female
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Maytansine / administration & dosage
  • Maytansine / adverse effects
  • Maytansine / analogs & derivatives*
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab / administration & dosage
  • Trastuzumab / adverse effects*

Substances

  • Antineoplastic Agents, Immunological
  • Maytansine
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Ado-Trastuzumab Emtansine